CARISMA Therapeutics (FRA:W2J) Net Income (Continuing Operations) : €-47.23 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CARISMA Therapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was €-8.57 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was €-47.23 Mil.

CARISMA Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for CARISMA Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Net Income (Continuing Operations) Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

-23.30

-36.09

-57.80

-79.67

-57.76

CARISMA Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial										-17.46	-10.37	-11.45	-16.84	-8.57

CARISMA Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-47.23 Mil.

CARISMA Therapeutics (FRA:W2J) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

CARISMA Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

CARM:USA

Address

3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines